Neurological Complications of Biological Treatment of Psoriasis

被引:12
作者
Ozog, Mateusz Kamil [1 ,2 ]
Grabarek, Beniamin Oskar [1 ,3 ,4 ,5 ]
Wierzbik-Stronska, Magdalena [6 ]
Swider, Magdalena [1 ]
机构
[1] Univ Technol Katowice, Fac Med, Dept Histol Cytophysiol & Embryol, PL-41800 Zabrze, Poland
[2] Med Univ Silesia, Fac Med, Dept Histol & Cells Pathol, PL-41800 Zabrze, Poland
[3] Univ Technol Katowice, Fac Med, Dept Gynecol & Obstet, PL-41800 Zabrze, Poland
[4] Ludwik Rydygier Mem Specialized Hosp, Dept Gynecol & Obstet Gynecol Oncol, PL-31826 Krakow, Poland
[5] TOMMED Specjalisci Zdrowia, Dept Gynecol & Obstet, PL-40662 Katowice, Poland
[6] Univ Technol Katowice, Fac Med, PL-41800 Zabrze, Poland
来源
LIFE-BASEL | 2022年 / 12卷 / 01期
关键词
psoriasis; biological treatment; anticytokine therapy; tumor necrosis factor alpha; nervous system; side effects; TUMOR-NECROSIS-FACTOR; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; MYASTHENIA-GRAVIS; THERAPEUTIC RECOMMENDATIONS; TNF; ETANERCEPT; ARTHRITIS; EVENTS; DEMYELINATION; THERAPIES;
D O I
10.3390/life12010118
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In the available literature, little attention has been paid to the assessment of psoriasis and the biological therapy used for it and the nervous system. The purpose of this article is to discuss the relationship between psoriasis and the nervous system as well as to analyze the mechanisms that lead to neurological complications during anticytokine therapies in psoriasis. However, this connection requires further analysis. The use of biological drugs in psoriasis, although it yields positive therapeutic results, is not without numerous side effects. Serious neurological side effects of the therapy are most often visible with the use of anti-TNF-alpha, which is why patients should be monitored for their potential occurrence. Early detection of complications and rapid discontinuation of treatment with the drug may potentially increase the patient's chances of a full recovery or improvement of his/her neurological condition. It also seems reasonable that, in the case of complications occurring during anti-TNF-alpha therapy, some of the drugs from other groups should be included in the therapy.
引用
收藏
页数:18
相关论文
共 105 条
[1]   Investigating the possible association between NLRP3 gene polymorphisms and myasthenia gravis [J].
Agah, Elmira ;
Nafissi, Shahriar ;
Saleh, Fatemeh ;
Sarraf, Payam ;
Tafakhori, Abbas ;
Mousavi, Seyed Vahid ;
Saghazadeh, Amene ;
Sadr, Maryam ;
Sinaei, Farnaz ;
Mohebbi, Bahareh ;
Mahmoudi, Mahdi ;
Shadi, Hamideh ;
Rezaei, Nima .
MUSCLE & NERVE, 2021, 63 (05) :730-736
[2]   Optic Neuritis Associated or Not with TNF Antagonists in Patients with Inflammatory Bowel Disease [J].
Alexandre, Benjamin ;
Vandermeeren, Yves ;
Dewit, Olivier ;
Moreels, Tom ;
de Boer, Nanne ;
Dhar, Anjan ;
Ziady, Chris ;
Shitrit, Ariella Bar-Gil ;
Steinwurz, Flavio ;
Jojic, Njegica ;
Costantino, Giuseppe ;
Bihin, Benoit ;
Rahier, Jean-Francois ;
Katsanos, Konstantinos H. .
JOURNAL OF CROHNS & COLITIS, 2016, 10 (05) :541-548
[3]   Neurological and psychiatric disorders in psoriasis [J].
Amanat, Man ;
Salehi, Mona ;
Rezaei, Nima .
REVIEWS IN THE NEUROSCIENCES, 2018, 29 (07) :805-813
[4]   Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis [J].
Bai, Fan ;
Zheng, Wen ;
Dong, Yan ;
Wang, Juan ;
Garstka, Malgorzata A. ;
Li, Ruilian ;
An, Jingang ;
Ma, Huiqun .
ONCOTARGET, 2018, 9 (01) :1266-1278
[5]  
Balak DMW, 2017, PSORIASIS-TARGETS TH, V7, P87, DOI 10.2147/PTT.S126727
[6]   Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date [J].
Beck, Kristen M. ;
Sanchez, Isabelle M. ;
Yang, Eric J. ;
Liao, Wilson .
PSORIASIS-TARGETS AND THERAPY, 2018, 8 :49-58
[7]   Cornoid Lamellation Revisited: Apropos of Porokeratosis With Emphasis on Unusual Clinicopathological Variants [J].
Biswas, Asok .
AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2015, 37 (02) :145-155
[8]   Clinical significance of positive anti-neutrophil cytoplasmic antibodies without evidence of anti-neutrophil cytoplasmic antibodies-associated vasculitis [J].
Bornstein, Gil ;
Ben-Zvi, Ilan ;
Furie, Nadav ;
Grossman, Chagai .
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2019, 22 (05) :940-945
[9]   Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination [J].
Brambilla, Roberta ;
Ashbaugh, Jessica Jopek ;
Magliozzi, Roberta ;
Dellarole, Anna ;
Karmally, Shaffiat ;
Szymkowski, David E. ;
Bethea, John R. .
BRAIN, 2011, 134 :2736-2754
[10]   Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs [J].
Broyles, Ana Dioun ;
Banerji, Aleena ;
Barmettler, Sara ;
Biggs, Catherine M. ;
Blumenthal, Kimberly ;
Brennan, Patrick J. ;
Breslow, Rebecca G. ;
Brockow, Knut ;
Buchheit, Kathleen M. ;
Cahill, Katherine N. ;
Cernadas, Josefina ;
Chiriac, Anca Mirela ;
Crestani, Elena ;
Demoly, Pascal ;
Dewachter, Pascale ;
Dilley, Meredith ;
Farmer, Jocelyn R. ;
Foer, Dinah ;
Fried, Ari J. ;
Garon, Sarah L. ;
Giannetti, Matthew P. ;
Hepner, David L. ;
Hong, David I. ;
Hsu, Joyce T. ;
Kothari, Parul H. ;
Kyin, Timothy ;
Lax, Timothy ;
Lee, Min Jung ;
Lee-Sarwar, Kathleen ;
Liu, Anne ;
Logsdon, Stephanie ;
Louisias, Margee ;
MacGinnitie, Andrew ;
Maciag, Michelle ;
Minnicozzi, Samantha ;
Norton, Allison E. ;
Otani, Iris M. ;
Park, Miguel ;
Patil, Sarita ;
Phillips, Elizabeth J. ;
Picard, Matthieu ;
Platt, Craig D. ;
Rachid, Rima ;
Rodriguez, Tito ;
Romano, Antonino ;
Stone, Cosby A., Jr. ;
Torres, Maria Jose ;
Verdu, Miriam ;
Wang, Alberta L. ;
Wickner, Paige .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2020, 8 (09) :S16-S116